Deals
CSL is advancing clazakizumab for the treatment of cardiovascular events in end-stage kidney disease and will retain rights over the asset in this indication. Lilly will explore other conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
When Eli Lilly and Company acquired Loxo Oncology for $8 billion, the company was gambling on several pipeline drugs in oncology.
Purdue Pharma may file for bankruptcy this week after negotiations over a multi-billion opioid claims settlement have stalled, multiple sources are reporting.
To accelerate development and commercialisation of innovative Glaucoma MIGS device, MINIjectTM
The Board of Directors of Cardea Bio and the Board of Directors of Nanosens Innovations have each authorized the respective companies to proceed with a proposed business combination.
Bordeaux, France, September 05th 2019 – LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery, announced that it has raised €6.2 million via a capital increase and non-dilutive funding.
BioCity, the pioneering life science incubator and business collective, has today announced investment in precision medicine biotech, Kinomica Ltd., via the Innovate UK Precision Medicine Investment Accelerator.
This week, Roche said it extended its tender-offer period for outstanding shares of Spark to Oct. 1 from Sept. 3.
TreeFrog Therapeutics, an expert stem cell company, announces that it has received close to €3M in non-dilutive funding from French and European programs.
MilliporeSigma has acquired all ownership rights to the ProcessPad™ platform from Simplyfeye Softwares Private Limited. The agreement includes the transfer of all copyrights and relevant intellectual property related to this software platform.